非小细胞肺癌活检标本ALK表达及临床病理特征分析
|
摘要
目的分析非小细胞肺癌活检标本人类间变性淋巴瘤激酶(ALK)表达及临床病理特征。方法方便选取接受治疗的非小细胞肺癌患者20例,选取时间为2017年7月—2018年6月,所有患者均接受免疫组织化学(immunohistochemistry,IHC)检测,分析患者的活检标本ALK表达和临床病理特征。结果在20例患者中,经CT和B超引导下穿刺的患者11例(55.00%),支气管镜的患者8例(40.00%),门诊手术切取标本的患者1例(5.00%);在20例非小细胞肺癌患者中,有腺癌患者16例(80.00%),鳞癌患者1例(5.00%),非特指型非小细胞肺癌3例(15.00%);患者年龄小于55岁的患者有8例(40.00%),大于55岁的患者有12例(60.00%);其中吸烟患者有8例(40.00%),不吸烟患者有12例(60.00%);免疫组织化学(IHC)检测的阳性患者2例(10.00%)。结论通过对非小细胞肺癌患者的活检标本ALK进行检测,可以对患者的病情进行协助诊断,并对患者的治疗具有指导作用。
Objective To analyze the expression and clinicopathological features of human anaplastic lymphoma kinase(ALK) in non-small cell lung cancer biopsy specimens. Methods 20 patients with non-small cell lung cancer who underwent treatment were convenient selected and enrolled. The patients were enrolled in the study from July 2017 to June 2018.All patients underwent immunohistochemistry(IHC) analysis. The biopsy specimens of ALK and pathological features were clinically analyzed. Results Of the 20 patients, 11 cases(55.00%) underwent CT and B-guided puncture, 8 cases(40.00%)patients underwent bronchoscopy, and 1 cases(5.00%) patients who underwent surgical surgery. Among the 20 patients with non-small cell lung cancer, 16 patients(80.00%) had adenocarcinoma, 1 patient(5.00%) had squamous cell carcinoma, and3 patients(15.00%) had non-specific non-small cell lung cancer. The patients were younger than 55 years old. There were8 patients(40.00%), and 12 patients(60.00%) were older than 55 years old; 8 cases(40.00%) were smokers and 12 cases(60.00%) were non-smokers; 2 cases(10.00%) cases of immunohistochemistry(IHC) positive patients were detected. Conclusion By detecting the biopsy specimen ALK in patients with non-small cell lung cancer, the patient's condition can be assisted and diagnosed, and the patient's treatment can be guided.
Objective To analyze the expression and clinicopathological features of human anaplastic lymphoma kinase(ALK) in non-small cell lung cancer biopsy specimens. Methods 20 patients with non-small cell lung cancer who underwent treatment were convenient selected and enrolled. The patients were enrolled in the study from July 2017 to June 2018.All patients underwent immunohistochemistry(IHC) analysis. The biopsy specimens of ALK and pathological features were clinically analyzed. Results Of the 20 patients, 11 cases(55.00%) underwent CT and B-guided puncture, 8 cases(40.00%)patients underwent bronchoscopy, and 1 cases(5.00%) patients who underwent surgical surgery. Among the 20 patients with non-small cell lung cancer, 16 patients(80.00%) had adenocarcinoma, 1 patient(5.00%) had squamous cell carcinoma, and3 patients(15.00%) had non-specific non-small cell lung cancer. The patients were younger than 55 years old. There were8 patients(40.00%), and 12 patients(60.00%) were older than 55 years old; 8 cases(40.00%) were smokers and 12 cases(60.00%) were non-smokers; 2 cases(10.00%) cases of immunohistochemistry(IHC) positive patients were detected. Conclusion By detecting the biopsy specimen ALK in patients with non-small cell lung cancer, the patient's condition can be assisted and diagnosed, and the patient's treatment can be guided.
引文
[1]高宁,郭江红,白玮,等.免疫组织化学和逆转录聚合酶链反应检测非小细胞肺癌间变性淋巴瘤激酶融合基因的比较研究[J].中国医师进修杂志,2016,39(9):842-845.
[2]赵静,赵金银,陈志霞,等.建立实时荧光定量逆转录PCR方法检测非小细胞肺癌棘皮动物微管相关蛋白4-间变淋巴瘤激酶融合基因[J].中国医学科学院学报,2016,38(6):643-649.
[3]唐艳萍,谭晓玉,蔡政民,等.非小细胞肺癌表皮生长因子受体基因突变和EML4-ALK融合基因表达的研究[J].检验医学与临床,2016,13(24):3458-3460.
[4]玛依拉·阿不都克力木,阿迪拉·斯依提,帕提古力·阿尔西丁.EML4-ALK融合基因在新疆维吾尔族非小细胞肺癌患者中的表达分析及其对预后的影响[J].湖南师范大学学报:医学版,2017,14(1):58-61.
[5]童永清,顾剑,郑红云,等.基于3'/5'端表达不平衡策略的荧光定量PCR法检测非小细胞肺癌患者血浆游离循环RNA中ALK融合基因[J].临床检验杂志,2017,35(8):587-589.
[6]Shuai Liu,Peng Chen,Yan-Wei Liu,et al.Role of Recursive Partitioning Analysis and Graded Prognostic Assessment on Identifying Non-Small Cell Lung Cancer Patients with Brain Metastases Who May Benefit from Postradiation Systemic Therapy[J].中华医学杂志:英文版,2018,131(10):1206-1213
[7]李玺,荣福.非小细胞肺癌经支气管针吸活检标本microRNA-126和microRNA-205的表达及意义[J].广东医学,2016,37(22):3393-3397.
[8]唐荣,郭蕾,刘秀云,等.非小细胞肺癌活检标本ALK表达及临床病理特征分析[J].中华病理学杂志,2016,45(9):642-643.
[9]王斯,李苗,王琳,等.非小细胞肺癌胸腔积液与配对肿瘤组织中EGFR基因突变检测的比较[J].现代肿瘤医学,201725(11):1729-1731.
[10]张美玲,李春,叶茂松,等.改良Blocker PCR检测EGFR-TKI耐药后非小细胞肺癌血浆EGFR T790M突变的价值[J].复旦学报:医学版,2018,45(1):45-51.
[11]方平,王沣,江富来,等.非小细胞肺癌表皮生长因子受体突变的检测与分子靶向治疗[J].中华肺部疾病杂志:电子版,2017,10(5):543-548.
[12]李锐,叶胜兵,何燕等.微滴数字PCR和突变扩增阻滞系统法检测不同类型非小细胞肺癌标本及血浆标本表皮生长因子受体基因突变情况比较[J].中华病理学杂志2017,46(11):764-768.
[13]方平,王沣.非小细胞肺癌患者功能性驱动基因突变的临床意义[J].中华诊断学电子杂志,2018,6(3):189-193.
[14]郭婷,王磊.非小细胞肺癌EGFR突变检测技术的研究进展[J].临床与病理杂志,2017,37(9):1936-1942.
[15]古丽那尔·阿布拉江,刘铭.肺癌活检标本的免疫组化检测在非小细胞肺癌鉴别诊断中的目的及意义[J].中外医疗,2018,37(10):1-3.
[2]赵静,赵金银,陈志霞,等.建立实时荧光定量逆转录PCR方法检测非小细胞肺癌棘皮动物微管相关蛋白4-间变淋巴瘤激酶融合基因[J].中国医学科学院学报,2016,38(6):643-649.
[3]唐艳萍,谭晓玉,蔡政民,等.非小细胞肺癌表皮生长因子受体基因突变和EML4-ALK融合基因表达的研究[J].检验医学与临床,2016,13(24):3458-3460.
[4]玛依拉·阿不都克力木,阿迪拉·斯依提,帕提古力·阿尔西丁.EML4-ALK融合基因在新疆维吾尔族非小细胞肺癌患者中的表达分析及其对预后的影响[J].湖南师范大学学报:医学版,2017,14(1):58-61.
[5]童永清,顾剑,郑红云,等.基于3'/5'端表达不平衡策略的荧光定量PCR法检测非小细胞肺癌患者血浆游离循环RNA中ALK融合基因[J].临床检验杂志,2017,35(8):587-589.
[6]Shuai Liu,Peng Chen,Yan-Wei Liu,et al.Role of Recursive Partitioning Analysis and Graded Prognostic Assessment on Identifying Non-Small Cell Lung Cancer Patients with Brain Metastases Who May Benefit from Postradiation Systemic Therapy[J].中华医学杂志:英文版,2018,131(10):1206-1213
[7]李玺,荣福.非小细胞肺癌经支气管针吸活检标本microRNA-126和microRNA-205的表达及意义[J].广东医学,2016,37(22):3393-3397.
[8]唐荣,郭蕾,刘秀云,等.非小细胞肺癌活检标本ALK表达及临床病理特征分析[J].中华病理学杂志,2016,45(9):642-643.
[9]王斯,李苗,王琳,等.非小细胞肺癌胸腔积液与配对肿瘤组织中EGFR基因突变检测的比较[J].现代肿瘤医学,201725(11):1729-1731.
[10]张美玲,李春,叶茂松,等.改良Blocker PCR检测EGFR-TKI耐药后非小细胞肺癌血浆EGFR T790M突变的价值[J].复旦学报:医学版,2018,45(1):45-51.
[11]方平,王沣,江富来,等.非小细胞肺癌表皮生长因子受体突变的检测与分子靶向治疗[J].中华肺部疾病杂志:电子版,2017,10(5):543-548.
[12]李锐,叶胜兵,何燕等.微滴数字PCR和突变扩增阻滞系统法检测不同类型非小细胞肺癌标本及血浆标本表皮生长因子受体基因突变情况比较[J].中华病理学杂志2017,46(11):764-768.
[13]方平,王沣.非小细胞肺癌患者功能性驱动基因突变的临床意义[J].中华诊断学电子杂志,2018,6(3):189-193.
[14]郭婷,王磊.非小细胞肺癌EGFR突变检测技术的研究进展[J].临床与病理杂志,2017,37(9):1936-1942.
[15]古丽那尔·阿布拉江,刘铭.肺癌活检标本的免疫组化检测在非小细胞肺癌鉴别诊断中的目的及意义[J].中外医疗,2018,37(10):1-3.